Camizestrant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerGastric CancerAdvanced Breast CancerEarly Breast CancerER+ HER2- Advanced Breast CancerHER2-Negative Breast Cancer

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Camizestrant

AstraZeneca

Phase 3

22

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

783

DATROWAY

Daiichi Sankyo

Preclinical

44

Megace

Bristol-Myers Squibb

Preclinical

45

Cymbalta

Alnylam Pharmaceuticals

Preclinical

36

Lexiscan

Astellas

Preclinical

17

Blenoxane

Bristol-Myers Squibb

Preclinical

18

Lupron

EEastern Cooperative Oncology Group

Preclinical

59

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

310

Zinecard

CChildren's Oncology Group

Preclinical

2Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Recruiting·AstraZeneca·Phase 3·NCT05774951·4,300 enrolled

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Not yet recruiting·MMedSIR·Phase 2·NCT07195227·150 enrolled

Advanced Breast Cancer2 trials

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Recruiting·AstraZeneca·Phase 2·NCT07427394·24 enrolled

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

Recruiting·AstraZeneca·Phase 3·NCT06380751·500 enrolled

Midazolam1 trial

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Completed·AstraZeneca·Phase 1·NCT06547164·40 enrolled

Tics1 trial

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Completed·AstraZeneca·Phase 1·NCT05551897·14 enrolled

Hepatic Impairment1 trial

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Completed·AstraZeneca·Phase 1·NCT05790304·22 enrolled

4 more indications

HER2-negative Breast Cancer1 trial

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

Recruiting·AstraZeneca·Phase 3·NCT07647328·150 enrolled

Early Breast Cancer1 trial

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Recruiting·AstraZeneca·Phase 3·NCT05952557·5,500 enrolled

ER+ HER2- Advanced Breast Cancer1 trial

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Recruiting·AstraZeneca·Preclinical·NCT06188520·564 enrolled

Gastric Cancer1 trial

DESTINY-Gastric02: T-DXd in Gastric Cancer

Completed·Daiichi Sankyo·Phase 2·NCT04644068·187 enrolled

Details

Drug Info

Related News